In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

The multimodal ArteraAI Prostate Test combines digital images of patients' biopsies and clinical data to predict prognoses and treatment outcomes.

NEW YORK – The US Food and Drug Administration has granted Nuevocor permission to begin a first-in-human trial of NVC-001, a gene therapy it is developing for LMNA-related dilated cardiomyopathy (LMNA ...

NEW YORK – Two newly minted leaders at the US Food and Drug Administration have drafted a new set of priorities for the agency, including modernizing the review process for drugs and devices and ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

The firm will use the funds to further develop its lead genetic medicine in Stargardt disease and advance its gene therapy pipeline in other indications.